Abstract
Sodium-glucose-transport-2 inhibitors (SGLT2i) reduce cardiovascular events in diabetics, but optimal timing of introduction remains unclear. A cost-effectiveness model compared strain-guided initiation of SGLT2i in elderly T2DM patients to alternatives.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
